The International Tissue and Tumor Repository for Chronic Arseniasis at the Armed Forces Institute of Pathology by Centeno, JA
Exposure to Peroxisome
Proliferators: Reassessment
of the Potential Carcinogenic
Hazard 
Melnick (1) recently suggested that because
peroxisome proliferation is not established as
an obligatory step in the carcinogenicity of
peroxisome proliferators (PPs), the proposal
that the peroxisome proliferator di(2-ethyl-
hexyl)phthalate (DEHP) poses no carcino-
genic risk to humans (2) due to species 
differences in peroxisome proliferation
should be viewed as an unvalidated hypothe-
sis (1). In this context, Melnick (1) raised
the recent downgrading by the International
Agency for Research on Cancer (IARC) of
DEHP (3) to “not classifiable as to its risk to
humans (group 3)” based on their conclu-
sion that it produces rodent liver tumors by
a mechanism involving peroxisome prolifer-
ation, which they judged to be not relevant
to humans (3). As illustrated by Melnick (1),
there is a large body of data to correlate the
phenomenon of rodent liver peroxisome
proliferation with rodent liver cancer but
“published studies have not established per-
oxisome proliferation per se as an obligatory
pathway on the carcinogenicity of DEHP”
(1). This focuses attention on the need, as
also suggested by O’Brien et al. (4), for a
fundamental review of how PPs induce liver
cancer in rodents and the relevance of these
rodent tumors for humans.
There are two distinct usage patterns
for PPs: as drugs such as clofibrate for the
treatment of hypolipidemia (5) and in non-
clinical applications such as the plasticiser
DEHP. Most PPs are carcinogenic to the
rodent liver, and the task of assessing their
human carcinogenic potential has fallen to
different regulatory agencies, depending on
the primary usage pattern of the particular
PP in question. There seems to be little
regulatory concern regarding the safety of
the clinical PPs, yet continuing uncertainty
regarding the safety of the nonpharmaceu-
tical PPs. This presents an untenable situa-
tion that we suggest is unjustified. 
Hypolipidemic fibrates such as clofibrate
and gemfibrozil have been used extensively
over the past 20 years to treat cardiovascular
disease and are enjoying a revival due to
recent reconfirmation of efficacy (6).
However, by 1980 several of these agents
had become associated with a rodent-specific
response known as hepatic peroxisome pro-
liferation (7), a property shared by a number
of nonpharmaceutical chemicals (8).
Additionally, a link between rodent liver
peroxisome proliferation and an increased
risk of rodent liver carcinogenesis was
emerging (7). Nonetheless, clinical side
effects of the fibrate PPs are rare, and analy-
ses of causes of death during treatment show
no evidence of an adverse effect and no evi-
dence of an increase in malignant disease
compared to the normal population (5).
Specifically, the carcinogenic risk to humans
of gemfibrozil and clofibrate has been for-
mally evaluated by IARC (9,10), and in the
case of clofibrate, for which most clinical
data exist, IARC (9) concluded that “the
mechanism of liver carcinogenesis in clofi-
brate-treated rats would not be operative in
humans.” This conclusion was based on the
observation that clofibrate causes peroxi-
some proliferation and cell proliferation in
rodent but not human hepatocytes and on
the results of extensive epidemiologic stud-
ies, particularly the World Health
Organization trial on clofibrate that includ-
ed 208,000 man-years of observation
(11,12). Further, a meta-analysis (13) of the
results from six clinical trials on clofibrate
also found no excess cancer mortality (9). 
It therefore appears that there are no
remaining concerns about  the human car-
cinogenic potential of the clinical PPs and
that the rodent liver effects have been set
aside as probable laboratory curiosities.
However, this is not true for the nonphar-
maceutical PPs; several regulatory agencies
continue to be concerned about their car-
cinogenic potential to the human liver. The
unease of these agencies is due to their
belief that in the absence of a definitive
mechanism of PP-induced rodent liver car-
cinogenesis, it is not possible to make a
clear statement on the human safety of
these chemicals. Nonetheless, there are now
several strong lines of evidence that PP-
induced rodent liver carcinogenesis is not
relevant to humans, which supports the
conclusion drawn by IARC for the clinical-
ly used PPs and the recent IARC decision
to downgrade DEHP from group 2B (pos-
sibly carcinogenic to humans) to group 3
(3).These lines of evidence are as follows:
• Direct genetic toxicity has been eliminated
as a common mechanism of carcinogenic
action for PPs in general (14). Thus, rodent
hepatocarcinogenicity must occur via a
nongenotoxic mechanism that correlates
with peroxisome proliferation, although, as
pointed out by Melnick (1), the hepatocar-
cinogenicity is unlikely to be caused by
peroxisome proliferation per se, as initially
suggested (15).
• There are marked species differences in the
induction of peroxisomes, with human
hepatocytes being resistant (8,16,17).
These data provide evidence that the phe-
nomenon of PP-induced peroxisome pro-
liferation is rodent specific.
• PPs suppress rodent hepatocyte apoptosis
(18–20) and induce rodent hepatocyte
replication (8). This duality of effects
provides a plausible mode of rodent car-
cinogenic action based on liver growth
perturbation (21,22). As well as being
resistant to peroxisome proliferation,
human hepatocytes are also resistant to
PP-mediated induction of replication and
suppression of apoptosis (8,16,17).
Whatever the precise mechanism by
which PPs induce rodent liver cancer,
rodent liver peroxisome proliferation,
induction of the peroxisomal gene acyl
CoA oxidase (ACO) (23), hypertrophy
(24), and carcinogenicity (25) are all medi-
ated through activation of the peroxisome
proliferator-activated receptor (PPARα).
This is illustrated dramatically by the
absence of all of these responses in PPARα
knockout mice treated with the PPs DEHP
or Wyeth-14,643 (24–26). 
Although human liver expresses around
10-fold less PPARα mRNA than the
rodent liver (27,28), evidence suggests that
the hypolipidemic effects of the fibrate
drugs in humans are also mediated by acti-
vation of PPARα, leading to regulation of
the apolipoprotein (Apo) genes such as
ApoA1 (29). Thus, PPARα levels in human
liver may be sufficient to mediate PP-
induced hypolipidemia, but insufficient to
activate the gene battery associated with
rodent peroxisome proliferation and cancer
(30). In addition to these quantitative data,
there are species differences in the molecular
sequence of the PPARα response elements
(PPREs) located upstream of genes associat-
ed with rodent peroxisome proliferation
such as ACO. In the rat, ACO responds to
PPs via a functional PPRE, whereas the
equivalent gene in humans does not
(31,32). Thus, the human ACO gene does
not respond to PPs even in the presence of
excess PPARα (31–33). Similarly, recent
data have shown that PPARα cannot
induce the battery of peroxisome prolifera-
tion-associated genes in human hepatoma
cells (33,34). Conversely, the human
ApoA1 gene is responsive to fibrate PPs,
whereas the equivalent rat gene is not (35).
Such findings isolate the human hypolipo-
daemic effects of PPs from the rodent can-
cer effects. 
Although the precise mechanism of the
carcinogenic action of PPs in the rodent
liver remains to be determined, all of the
phenomena associated with this response of
rodent hepatocytes (peroxisome prolifera-
tion, ACO gene expression, induction of
cell proliferation, and the suppression of
apoptosis) are absent in human hepatocytes.
This body of data provides a plausible mode
of carcinogenic action for the rodent liver,
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demiology showing an absence of a human
cancer risk, provides substantial weight of
evidence that the PP class of nongenotoxic
rodent hepatocarcinogens does not pose a
potential cancer hazard to the human liver.
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Peroxisome Proliferators:
Response
The comments from Roberts et al. regarding
my commentary (1) on whether human and
mechanistic data provide a sufficient ratio-
nale to dismiss DEHP cancer risks because
of species differences in peroxisome prolifer-
ation reveal both agreements and disagree-
ments on this issue. We agree that the 
animal carcinogenicity data are irrefutable
and, as written by Roberts et al., we agree
that “the hepatocarcinogenicity [of peroxi-
some proliferators (PPs)] is unlikely to be
caused by peroxisome proliferation per se.”
In addition, we agree that the mechanisms
of carcinogenic action of DEHP and other
PPs remain to be determined. 
Where we differ is on our views of what
constitutes sufficient evidence to dismiss
positive animal cancer data as being indica-
tive of possible human cancer risk, as well
as on interpretations of available data.
From a public health perspective, it is
important to reexamine the basis on which
Roberts et al. conclude that rodent liver
carcinogenesis induced by PPs “is not rele-
vant to humans” while acknowledging that
the mechanisms of carcinogenesis of PPs
have not been established. 
With respect to available human data,
Roberts et al. refer to clinical studies on
clofibrate and gemfibrozil in male subjects
as providing evidence of “an absence of a
human cancer risk” for fibrate PPs. In a
previous review of these data, Ashby et al.
(2) noted a small increase in basal cell carci-
nomas of the skin in gemfibrozil-treated
patients, but concluded that the epidemio-
logic studies on hypolipidemic drugs “are
of limited value only, because of the short
time periods involved.” The World Health
Organization trial on the prevention of
ischemic heart disease by clofibrate was last
updated in 1982 and included 13 years of
observation, 5 years during the treatment
period plus 8 years of follow-up (3). That
study revealed an excess of deaths for non-
malignant diseases of the liver, gall bladder,
and intestines in the clofibrate-treated
group compared to controls. Because the
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latency period for clinical manifestation of
cancer may be 20 years or more postexpo-
sure, the current data are insufficient to
permit a definitive conclusion on the pres-
ence or absence of a causal association
between exposure to fibrate lipid-lowering
drugs and human cancer (4). It is not clear
why Roberts et al. claim that “there are no
remaining concerns about the human car-
cinogenic potential of the clinical PPs”
inasmuch as a previous review from their
laboratory of the same epidemiologic stud-
ies found these data to be of limited value
due to short study durations (2), and there
are no available studies on female cancer
risk. Furthermore, in contrast to the view
given by Roberts et al., the Physicians’ Desk
Reference (5) warns 
of the tumorigenicity of clofibrate [and of gemfi-
brozil (6)] in rodents and the possible increased
risk of malignancy associated with clofibrate in
the human.
For DEHP, no epidemiologic studies have
been reported.
Roberts et al. also conclude that PPs
would “not pose a potential cancer hazard to
the human liver.” However, as I noted previ-
ously (1), it might not be appropriate to
expect exact site correspondence for effects
of PPs in rodents and humans because of
species differences in tissue expression of
PPARs. For example, the demonstration of a
functional PPAR in human breast cancer cell
lines (7) and the finding of enhanced cell
proliferation by DEHP in human breast
cancer cells (8) indicate a possible breast can-
cer risk. Furthermore, liver is not the only
target organ of tumor induction by hepatic
PPs. Several PPs induce tumors of the testis
and pancreas in laboratory animals, and
tumor induction at these sites occurs with-
out induction of peroxisomes in these
affected organs (9).
Roberts et al. claim that available data
provide “a plausible mode of carcinogenic
action” for PPs, which is based on induc-
tion of hepatocyte proliferation and sup-
pression of apoptosis. The latter effects are
reported to be absent in cultured human
hepatocytes. However, as noted in the
Physicians’ Desk Reference (5,6), 
changes in peroxisome morphology and numbers
have been observed in humans after treatment
with several members of the fibrate class, includ-
ing clofibrate, when liver biopsies were compared
before and after treatment in the same individual.
Several additional issues influence the plau-
sibility of the mode of action for liver car-
cinogenicity claimed by Roberts et al.: 
• Their hypothesis has not been challenged
or demonstrated experimentally. For exam-
ple, no studies have established time- and
dose-dependent associations between
tumor induction and hepatocyte prolifera-
tion and suppression of apoptosis in labora-
tory animals treated with various PPs. 
• It is important to recognize that procedures
used to harvest hepatocytes from human
livers are usually very different from those
used to culture rodent hepatocytes. To
evaluate possible functional loss during the
time after death until culturing of human
hepatocytes, I stressed the critical need to
include demonstration of apolipoprotein
A-II (ApoA-II) induction in studies on the
responsiveness of human hepatocytes to
PPs (1). ApoA-II mRNA has been shown
to be induced in human hepatocytes via
PPAR activation (10). Thus, measurements
of ApoA-II induction provide a necessary
control to decipher the absence of an effect
as being due to the lack of responsiveness
to PPs rather than lack of transcriptional
function in human cell cultures.
• Because tumor induction by PPs requires
long-term exposure, the mechanistic steps
in this process most likely involve sus-
tained rather than transient effects. In the
case of DEHP and several other PPs, hepa-
tocyte proliferation is not a sustained
response with continued exposure (11).
Further, cell culture studies are usually
performed over a period of a few days and
therefore cannot distinguish a sustained
response from a transient effect. 
• Mechanistic studies in normal human
hepatocytes may be focusing on the wrong
cell population. Cattley et al. (12) provided
data that indicate that the mechanism of
liver tumor induction by PPs may be more
relevant to changes that are induced in
preneoplastic foci rather than in normal
hepatocytes. 
• Several studies demonstrate that DEHP
induces biological effects independent of
peroxisome proliferation [e.g., morphologic
cell transformation and decreased levels of
gap junction intercellular communication
(13)]. Roberts et al. ignore the possibility
that some of these responses may also con-
tribute to the carcinogenic process. Roberts
et al. cite the 11-month study of Wy14,643
in PPARα knockout mice (14) as evidence
that the carcinogenicity of PPs are mediated
by PPARα. However, as I noted previously
(1), unlike this mouse model, humans do
not lack a functional PPARα, and an 11-
month study is not adequate to detect late-
developing tumors that might arise by
mechanisms independent of PPARα.
• Roberts et al. cite the finding of an inactive
PP response element upstream of the acyl
CoA oxidase gene in a sample human pop-
ulation (15) as additional evidence for why
humans may be less responsive than
rodents to PPs. However, induction of acyl
CoA oxidase is not relevant to the suggest-
ed carcinogenic mode of action for DEHP
and other PPs. Obviously, further work is
needed to characterize the expression of all
genes that may be affected by PPs in
diverse populations.
The inappropriate dismissal of positive
animal cancer findings in assessments of
human risk could have serious health con-
sequences. Protection of public health
requires rigorous testing and validation of
mechanistic hypotheses rather than reliance
on assertions of plausibility.
Ronald Melnick
National Institute of Environmental
Health Sciences
Research Triangle Park, NC
E-mail: melnickr@niehs.nih.gov
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The International Tissue and
Tumor Repository for Chronic
Arseniasis at the Armed
Forces Institute of Pathology
The public health concern for environmen-
tal exposure to arsenic has been widely rec-
ognized for decades. However, recent
human activities have resulted in even
greater arsenic exposures and the potential
increase for chronic arsenic poisoning on a
worldwide basis. This is especially the case
in China, Taiwan, Thailand, Mexico, Chile,
India, and Bangladesh. The sources of
arsenic exposure vary from burning arsenic-
rich coal (China) (1) and mining activities
(Malaysia, Japan) to the ingestion of arsenic-
contaminated drinking water (Taiwan,
Inner Mongolia, China) (2). The ground-
water arsenic contamination in Bangladesh
and the West Bengal Delta of India has
received the greatest international attention
due to the large number of people exposed
and the high prevalence of arsenic-induced
diseases (3). Recent estimates suggest that in
West Bengal as many as 20–30 million peo-
ple are at risk from drinking arsenic-conta-
minated water obtained from thousands of
tube wells that appear to be contaminated
with naturally occurring arsenic. 
Although the health effects associated
with chronic arsenic exposure have been
reasonably well characterized in those areas
around the world with high arsenic levels in
their drinking water, the association of
adverse health effects with arsenic exposure
in the United States is less clear. This is pri-
marily due to the lower exposure levels in
the great majority of U.S. drinking water
supplies and the lack of research studies
that look for health effects in arsenic-
exposed persons.
Cancer is a well-established arsenic-
related disease, although the cancer risk at
low level exposure is unclear. Equally
unclear is whether low-level arsenic expo-
sures may play a role in the incidence in
non-cancer heath problems in the United
States such as immune suppression and car-
diovascular disease. This uncertainty in
dose effects at low levels has resulted in
hotly debated differences in opinion as to
the need for stricter government regulation
of arsenic in drinking water. Recently, the
National Research Council studied the
issue and determined that the current
drinking water standard for arsenic is too
high and recommended that it be lowered
(4). The U.S. Environmental Protection
Agency (U.S. EPA), in fact, has proposed
lowering the allowable drinking water stan-
dard from 50 µg/L to 10 µg/L. The drink-
ing water industry, however, opposes
changing the standard on the basis that
more information is needed as to how
arsenic causes cancer and other health
effects, and whether these mechanisms
operating at high dose levels also operate at
low levels as well.
It is true that the mechanisms by which
arsenic may induce adverse health effects
are largely unknown. There are two major
reasons for this. One is that the sophisticat-
ed molecular probes needed to study cellu-
lar and biochemical mechanisms have only
recently become available, whereas most of
the toxicity studies with arsenic were con-
ducted many years before their availability.
A second, equally important reason is that
properly fixed human tissues from arsenic-
exposed persons are not available for such
sophisticated research studies. The dilemma
we face is that now we have the research
tools (with even more sophisticated meth-
ods on the horizon), but we do not have
the human tissues to study. 
The Armed Forces Institute of
Pathology (AFIP) is participating in an
international research effort aimed at the
development of an International Tissue and
Tumor Repository for Chronic Arseniasis in
Humans (ITTRCA). This effort is support-
ed by four other federal agencies, including
the U.S. EPA, the National Cancer
Institute, the National Institute of Environ-
mental Health Sciences, and the U.S.
Geological Survey. The main objective of
the ITTRCA is to obtain and archive tissues
from persons known to or suspected of hav-
ing been exposed to arsenic (environmental
or occupational) and exhibiting adverse
health effects. A component of this reposito-
ry is to provide a mechanism by which the
underlying pathology and morphology of
arsenic-induced lesions can be described (5).
The major thrust of the ITTRCA is to facil-
itate the formulation of a standardized sys-
tem of nomenclature for the study of skin
lesions and other arsenic-induced changes in
tissues, to foster the use of archival materials
for the development of international collab-
orative projects on arsenic health effects, to
facilitate the use and accessibility of archival
materials associated with arsenic exposure,
and to develop interlaboratory trials for the
analysis and speciation of arsenic in biologi-
cal tissues. Another unique component of
the ITTRCA is the link to a repository of
sources (coal, ores, soil, water) for arsenic
exposures organized and maintained by the
U.S. Geological Survey.
We request that pathologists, clinicians,
epidemiologists, toxicologists, and public
health professionals in the United States
and throughout the world participate in
this exciting international project. Please
contact us for further information about
the ITTRCA and the methods for collec-
tion and shipment of tissues. 
Jose A. Centeno
Florabel G. Mullick
U.S. Armed Forces Institute of Pathology
Washington, D.C.
E-mail: centeno@afip.osd.mil
Telephone: (202) 782-2839
Herman Gibb
U.S. EPA, National Center for
Environmental Assessment
Washington, D.C.
David Longfellow
National Cancer Institute
Bethesda, Maryland
Claudia Thompson
National Institute of Environmental 
Health Sciences
Research Triangle Park, North Carolina
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